EKSO vs. QLI, BCLI, ONCT, LUMO, MRM, LYRA, ITRM, BIAF, FBRX, and XGN
Should you be buying Ekso Bionics stock or one of its competitors? The main competitors of Ekso Bionics include Qilian International Holding Group (QLI), Brainstorm Cell Therapeutics (BCLI), Oncternal Therapeutics (ONCT), Lumos Pharma (LUMO), MEDIROM Healthcare Technologies (MRM), Lyra Therapeutics (LYRA), Iterum Therapeutics (ITRM), bioAffinity Technologies (BIAF), Forte Biosciences (FBRX), and Exagen (XGN). These companies are all part of the "medical" sector.
Ekso Bionics (NASDAQ:EKSO) and Qilian International Holding Group (NASDAQ:QLI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
Ekso Bionics received 317 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. However, 100.00% of users gave Qilian International Holding Group an outperform vote while only 57.50% of users gave Ekso Bionics an outperform vote.
Qilian International Holding Group has a net margin of 0.00% compared to Ekso Bionics' net margin of -79.48%. Qilian International Holding Group's return on equity of 0.00% beat Ekso Bionics' return on equity.
Ekso Bionics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
6.4% of Ekso Bionics shares are held by institutional investors. 7.5% of Ekso Bionics shares are held by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Qilian International Holding Group had 1 more articles in the media than Ekso Bionics. MarketBeat recorded 2 mentions for Qilian International Holding Group and 1 mentions for Ekso Bionics. Qilian International Holding Group's average media sentiment score of 0.22 beat Ekso Bionics' score of 0.00 indicating that Qilian International Holding Group is being referred to more favorably in the news media.
Qilian International Holding Group has higher revenue and earnings than Ekso Bionics.
Ekso Bionics presently has a consensus target price of $10.00, suggesting a potential upside of 635.29%. Given Ekso Bionics' higher possible upside, research analysts clearly believe Ekso Bionics is more favorable than Qilian International Holding Group.
Summary
Qilian International Holding Group beats Ekso Bionics on 9 of the 14 factors compared between the two stocks.
Get Ekso Bionics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EKSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ekso Bionics Competitors List
Related Companies and Tools
